Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19
Clinical Trial
[키워드] absolute neutrophil count
acute phase reactant
acute respiratory distress
administration
adverse event
Allogeneic
ARDS
average
bone
Bone marrow
C-reactive protein
CD3
CD4
CD8
clinical status
cohort study
COVID-19
criteria
Critically ill
Cytokine storm
D-dimer
declined
determine
downregulate
Efficacy
evaluated
Exosome
expired
ferritin
fraction
Future
Immunity
improvement
intravenous dose
Lymphocyte count
lymphopenia
Marrow
MSC
nonrandomized
Open-label
oxygen
Oxygenation
p value
PaO
Patient
polymerase chain
provided
Randomized controlled trial
RCTs
reduction
remained
safety endpoint
safety profile
SARS-CoV-2
severe COVID-19
single hospital
STEM
stem cell
survival rate
syndrome
therapeutic
therapeutic potential
Treatment
[DOI] 10.1089/scd.2020.0080 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1089/scd.2020.0080 PMC 바로가기 [Article Type] Clinical Trial